Ester Muñoz-Aceituno

Ms. Ester Muñoz-Aceituno

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2020 in Medicina
Verified
Journal Article
Open access
PDF file
EMEster Muñoz-Aceituno
Ester Muñoz-Aceituno
LMLuisa Martos-Cabrera
Luisa Martos-Cabrera
MOMaría Carmen Ovejero-Benito
María Carmen Ovejero-Benito
ARAlejandra Reolid
Alejandra Reolid
Francisco Abad-SantosFrancisco Abad-Santos
Francisco Abad-Santos
EDEsteban Dauden
Esteban Dauden
Background and objectives: Psoriasis is a chronic immune-mediated skin disease caused by several complex factors, both environmental and genetic, many of which are still not fully understood. Nowadays, several groups of biological drugs are being used for psoriasis treatment. Although these therapies are very effective, they show significant variability in efficacy among individuals. Therefore, there is a need for biomarkers to predict treatment outcomes in order to guide personalized therapeutic decisions. Pharmacogenetics is the study of variations in DNA sequences related to drug response. Materials and Methods: In this article, we review pharmacogenetics studies on the treatment of moderate-to-severe psoriasis focusing on anti-interleukin (IL) 12/23 (ustekinumab) and anti-IL17 drugs (secukinumab and ixekizumab), as well as recent studies concerning anti-TNF drugs. Results: Several polymorphisms have been studied over the years in reference to anti-TNF drugs; some of the most recent studies included the performance of a genome-wide association study (GWAS) and pharmacogenetics studies focused on the optimization of a treatment regimen. Various polymorphisms in different genes have been related to ustekinumab response; among them, the most commonly studied is the HLA-C*06:02 allele. Conclusions: Although not confirmed in some studies, most studies have shown that patients carrying this allele present a significantly higher response rate to ustekinumab. Some polymorphisms have been studied in patients treated with anti-IL17 drugs, mostly related to secukinumab; however, up to now, no association has been found between any of these polymorphisms and response. Nevertheless, further studies involving larger cohorts are needed in order to confirm these results before the implementation of this biomarker in clinical practice.

17 February 2019 in Pediatric Dermatology
Verified
Journal Article
Closed access
PDF file
EMEster Muñoz-Aceituno
Ester Muñoz-Aceituno
ICIsabel Colmenero
Isabel Colmenero
BGBeatriz González‐Meli
Beatriz González‐Meli
ATAntonio Torrelo
Antonio Torrelo
ÁHÁngela Hernández-Martín
Ángela Hernández-Martín

1 October 2020 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
EMEster Muñoz-Aceituno
Ester Muñoz-Aceituno
RVRocío Vega‐González
Rocío Vega‐González
MMMaría Martínez‐Palazuelos
María Martínez‐Palazuelos
SPSilvia Pérez‐Gala
Silvia Pérez‐Gala
MLMar Llamas-Velasco
Mar Llamas-Velasco
EDEsteban Dauden
Esteban Dauden

17 August 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
MLMar Llamas-Velasco
Mar Llamas-Velasco
ARAlejandra Reolid
Alejandra Reolid
ASAncor Sanz-Garcia
Ancor Sanz-Garcia
LAL. Alonso‐Guirado
L. Alonso‐Guirado
JMJorge García Martínez
Jorge García Martínez
MOMaría Carmen Ovejero-Benito
María Carmen Ovejero-Benito

9 June 2020 in Photodermatology, Photoimmunology & Photomedicine
Verified
Journal Article
Closed access
PDF file
EMEster Muñoz-Aceituno
Ester Muñoz-Aceituno
ARAlejandra Reolid
Alejandra Reolid
PRPedro Rodríguez‐Jiménez
Pedro Rodríguez‐Jiménez
PCPablo Chicharro
Pablo Chicharro
DADiego de Argila
Diego de Argila

4 September 2022 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
ARAlejandra Reolid
Alejandra Reolid
ASAntonio Sahuquillo-Torralba
Antonio Sahuquillo-Torralba
ASAncor Sanz-Garcia
Ancor Sanz-Garcia
RBRafael Botella-Estrada
Rafael Botella-Estrada
EMEster Muñoz-Aceituno
Ester Muñoz-Aceituno
MOMaría Carmen Ovejero-Benito
María Carmen Ovejero-Benito
Background: Psoriasis can present different phenotypes and could affect diverse body areas. In contrast to the high effectiveness of biological drugs in the treatment of trunk and extremities plaque psoriasis, in palmoplantar phenotypes and in plaque scalp psoriasis, these same drugs usually have reduced efficacy. Anti-TNF drugs could induce the appearance of palmoplantar pustulosis (PPP) in patients with other inflammatory diseases. The objective of this study is to identify if there are DNA Copy Number Variations (CNVs) associated with these different clinical phenotypes, which could justify the differences found in clinical practice. Moreover, we intend to elucidate if anti-TNF-induced PPP has a similar genetic background to idiopathic PPP. Methods: Skin samples were collected from 39 patients with different patterns of psoriasis and six patients with anti-TNF-induced PPP. The CNVs were obtained from methylation array data (Illumina Infinium Human Methylation) using the conumee R package. Results: No significant CNVs were found between the different phenotypes and the locations of psoriasis compared. Nevertheless, we found two significant bins harboring five different genes associated with anti-TNF-induced PPP in patients with a different background other than psoriasis. Conclusions: Our results may help to predict which patients could develop anti-TNF-induced PPP.